Lys305
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys305  -  PKM (human)

Site Information
GIEIPAEkVFLAQkM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 474712

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 , 6 ) , immunoprecipitation ( 1 , 6 ) , mass spectrometry ( 1 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ) , modification-specific antibody ( 1 , 6 ) , mutation of modification site ( 1 , 6 ) , western blotting ( 1 , 6 )
Disease tissue studied:
breast cancer ( 1 ) , liver cancer ( 35 ) , hepatocellular carcinoma ( 35 ) , lung cancer ( 1 , 6 ) , non-small cell lung cancer ( 1 , 6 ) , prostate cancer ( 6 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
glucose ( 6 ) , low_glucose ( 1 ) , nicotinamide ( 6 ) , serum_starvation ( 1 ) , siRNA ( 1 , 6 ) , trichostatin_A ( 1 , 6 )

Downstream Regulation
Effects of modification on PKM:
enzymatic activity, induced ( 1 ) , enzymatic activity, inhibited ( 6 ) , intracellular localization ( 6 ) , molecular association, regulation ( 6 ) , protein degradation ( 6 )
Effects of modification on biological processes:
autophagy, induced ( 6 ) , carcinogenesis, induced ( 1 , 6 ) , cell growth, induced ( 6 )
Induce interaction with:
HSC70 (human) ( 6 )
Inhibit interaction with:
Other ( 6 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 1 ) , prostate cancer ( 6 )

References 

1

Park SH, et al. (2016) SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Res 76, 3802-12
27197174   Curated Info

2

Wang P, Sun C, Zhu T, Xu Y (2015) Structural insight into mechanisms for dynamic regulation of PKM2. Protein Cell 6, 275-87
25645022   Curated Info

3

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

6

Lv L, et al. (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42, 719-30
21700219   Curated Info

7

Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786   Curated Info

8

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

9

Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

10

Cherry J (2007) CST Curation Set: 2727; Year: 2007; Biosample/Treatment: cell line, KMS-18/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

11

Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

12

Cherry J (2007) CST Curation Set: 2513; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

13

Cherry J (2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

14

Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

15

Cherry J (2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

16

Guo A (2007) CST Curation Set: 2324; Year: 2007; Biosample/Treatment: cell line, NCI-H1650/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

17

Possemato A (2006) CST Curation Set: 2188; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

18

Li Y (2006) CST Curation Set: 1971; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

19

Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

20

Li Y (2006) CST Curation Set: 1828; Year: 2006; Biosample1/Treatment/Isotope: cell line, SW620/serum starved &'||' serum starved/L, Biosample2/Treatment/Isotope: cell line, SW620/serum starved/TSA/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

21

Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'||' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

22

Li Y (2006) CST Curation Set: 1658; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

23

Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

24

Li Y (2006) CST Curation Set: 1641; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

25

Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

26

Li Y (2006) CST Curation Set: 1633; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

27

Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

28

Li Y (2006) CST Curation Set: 1565; Year: 2006; Biosample/Treatment: cell line, SW48/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

29

Li Y (2006) CST Curation Set: 1566; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

30

Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

31

Li Y (2006) CST Curation Set: 1469; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

32

Li Y (2006) CST Curation Set: 1472; Year: 2006; Biosample/Treatment: cell line, HCT15/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

33

Li Y (2006) CST Curation Set: 1475; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

34

Li Y (2006) CST Curation Set: 1476; Year: 2006; Biosample/Treatment: cell line, HCT8/S11/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

35

Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info